Profound Medical PROF
5.76
0.16
2.86%
as of 25 Sep
- Market cap
- $204.6M
- P/E
- 0.0×
Follow PROF
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
12.67 | 12.50 | 14.78 | 10.30 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(21.32) | (27.40) | (36.24) | (15.31) | |
P/B ratio |
4.85 | 3.96 | 3.58 | 4.58 | |
Price to Tangible BV |
4.87 | 3.97 | 3.59 | 4.60 | |
EV/Sales |
11.13 | 10.31 | 11.63 | 9.19 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.89) | (5.04) | (4.90) | (3.50) | |
EV/FCF |
(5.78) | (4.95) | (4.82) | (3.45) | |
Quick Ratio |
5.25 | 5.63 | 11.02 | 3.32 | |
Current Ratio |
6.46 | 6.56 | 12.52 | 4.18 | |
Net Debt/EBITDA |
3.09 | 5.78 | 7.61 | 2.32 | |
Debt/Assets |
7.22% | 6.13% | 5.81% | 10.59% | |
Debt/Equity |
0.09 | 0.08 | 0.07 | 0.14 | |
Asset Turnover |
0.34 | 0.28 | 0.22 | 0.34 | |
Operating CF/Net income |
1.19 | 1.22 | 0.80 | 1.21 | |
Capex/Depreciation |
0.00 | 0.00 | (2.22) | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
227.71% | 98.59% | 71.47% | 102.44% | |
Selling, General and Administrative Expense of Revenue |
296.38% | 123.50% | 118.59% | 140.40% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
35.20% | 19.64% | 23.11% | 31.56% | |
Graham Net Nets |
0.19 | 0.24 | 0.27 | 0.21 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(14.74%) | (19.14%) | (17.92%) | (27.40%) | |
Free Cash Flow Yield |
(15.20%) | (16.65%) | (16.33%) | (25.89%) | |
Revenue per Share |
0.07 | 0.15 | 0.20 | 0.18 | |
Operating CF per Share |
(0.31) | (0.24) | (0.22) | (0.32) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.31) | (0.24) | (0.23) | (0.32) | |
Cash per Share |
1.05 | 1.39 | 1.98 | 0.82 | |
Shareholders Equity per Share |
1.37 | 1.64 | 2.20 | 1.07 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.37 | 1.64 | 2.20 | 1.07 | |
Free Cash Flow |
(11.34) | (8.58) | (6.81) | (9.61) | |
Working Capital |
49.75 | 58.92 | 70.01 | 31.59 | |
Capital Expenditures |
— | — | (0.24) | — | |
Net Current Asset Value |
46.29 | 55.50 | 65.05 | 31.36 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.04 | 0.00 | |
Net Profit Margin |
(384.21%) | (132.15%) | (136.76%) | (150.82%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
7.26 | 7.69 | 7.12 | 7.60 | |
Average Payables |
0.95 | 1.60 | 1.44 | 2.06 | |
Average Inventory |
9.40 | 7.90 | 7.02 | 7.39 | |
Average Assets |
56.03 | 67.16 | 73.85 | 42.27 | |
Average Common Equity |
44.53 | 55.11 | 63.43 | 31.60 |
Columns are period end dates